Pharma: Page 2

  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images

    Merck builds out cancer drug pipeline with Kelun-Biotech deal

    The pharma will pay the Chinese drugmaker $175 million for access to seven preclinical antibody-drug conjugates, deepening ties established this year. 

    By Dec. 22, 2022
  • Biogen
    Image attribution tooltip
    Permission granted by Biogen

    Roche, Biogen sign royalty deal for late-stage lymphoma drug

    Roche will pay royalties to Biogen on glofitimab, part of a long-standing collaboration between the two companies that’s resulted in Rituxan and Ocrevus.

    By Updated Dec. 26, 2022
  • Single strand ribonucleic acid, RNA research Explore the Trendline
    Image attribution tooltip
    luismmolina via Getty Images

    The expanding world of RNA therapies

    Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

    By BioPharma Dive staff
  • Lilly partners with Sosei to develop drugs aimed at a key family of proteins

    The pharma will pay Sosei $37 million upfront to discover new candidates for diabetes and metabolic diseases that target G protein-coupled receptors.

    By Dec. 16, 2022
  • Lilly lays out ambitious plans for 2023

    Expected increases in sales and spending will be accompanied by a lengthy clinical and regulatory agenda in diabetes, obesity and Alzheimer’s disease.

    By Dec. 14, 2022
  • Bill Anderson, pharmaceuticals division chief executive officer.
    Image attribution tooltip
    Courtesy of Roche

    Roche pharma division head to depart amid CEO changeover

    The drugmaker’s pharmaceuticals head Bill Anderson will leave on Dec. 31. Current diagnostics chief Thomas Schinecker will fill in on an interim basis before a replacement is found and Schinecker takes over as CEO in March.

    By Dec. 12, 2022
  • This is the cover image for the podcast series Thinking Big for Small and Mid-Sized Biotechs.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Sponsored by Allucent

    [Podcast] Thinking Big for Small and Mid-Sized Biotechs

    This podcast series explores how to help small and mid-sized companies get innovative treatments to the people who need help small and mid-sized companies get innovative treatments to the people who need them.

    By BioPharma Dive's studioID • Updated Dec. 15, 2022
  • Pharma professionals collaborating on whiteboard.
    Image attribution tooltip

    iStock / Fizkes

    Sponsored by Aspirant

    How can growth-oriented pharma organizations ensure they are ‘fit for purpose’?

    The pharmaceutical industry is dynamic and rapidly evolving. To compete, companies must learn to leverage the pace of change as an accelerator for both shareholder returns and patient outcomes.

    Dec. 12, 2022
  • Novartis gets second trial win for blockbuster hopeful

    The company plans to seek broad approval of the oral medication, iptacopan, next year after it met its primary endpoint in a new pool of patients with the rare blood disease PNH.

    By Kristin Jensen • Dec. 8, 2022
  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    MEI, Kyowa stop lymphoma drug trials after FDA meeting

    The decision not to run a Phase 3 trial is the latest fallout from U.S. regulators’ recent moves to closely evaluate a class of drugs called PI3 kinase inhibitors. 

    By Dec. 6, 2022
  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan / Industry Dive

    J&J drops out of hunt for Horizon, leaving Sanofi and Amgen to bid

    The two remaining suitors said they would make cash bids if they move forward with offers, for which they must declare “firm intent” by Jan. 10 under Irish takeover rules.

    By Dec. 5, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J’s Duato to replace departing Gorsky as board chair

    The board reshuffling will consolidate Duato’s leadership of J&J as the company absorbs a big medtech acquisition and nears a planned spin out of its consumer health division.

    By Dec. 2, 2022
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Large pharmas probe takeover of Horizon Therapeutics

    The Dublin-headquartered drugmaker confirmed it is in "highly preliminary" talks with Amgen, J&J and Sanofi, although it cautioned no offer may ever materialize.

    By Updated Nov. 30, 2022
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images

    Roche pulls Tecentriq in bladder cancer, completing sweep of ‘dangling’ accelerated approvals

    The pharma will no longer market the immunotherapy in the U.S. for urothelial carcinoma, the indication for which the drug was first approved six years ago.

    By Nov. 29, 2022
  • Medicine bottles
    Image attribution tooltip
    XH4D via Getty Images
    Sponsored by Cognizant

    Is your gross-to-net strategy ready for uncertainty?

    Whether economic times are good, bad or somewhere in between, life science companies benefit from a holistic, centralized approach, including technological, financial, operational and regulatory considerations for GtN management and predictability of GtN rates.

    Nov. 28, 2022
  • Blood smear on microscopic film shows the malaria parasite Plasmodium falciparum.
    Image attribution tooltip
    Md Ariful Islam via Getty Images

    Novartis, research group to advance new kind of malaria drug into late-stage test

    The Swiss pharma and the Medicines for Malaria Venture plan to start a Phase 3 trial of a non-artemisinin combination treatment next year.

    By Nov. 23, 2022
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.

    Merck to buy blood cancer biotech Imago for $1.35B

    The deal is Merck’s second notable acquisition in the past year and a half, part of a strategy to diversify its pipeline beyond the top-selling Keytruda.

    By Nov. 21, 2022
  • Scientists working in an R&D laboratory
    Image attribution tooltip
    Courtesy of Merck KGaA

    Merck KGaA outlines plan to rev up drug R&D

    The German company aims to, on average, launch a new medicine or major treatment indication every 18 months in a bid to boost its pharma business.

    By Nov. 21, 2022
  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical

    Teva taps Sandoz veteran to take over CEO post from Schultz

    Richard Francis will take over for the retiring Kåre Schultz on Jan. 1. He’ll face major challenges at Teva, including opioid settlements, biosimilar launches and reducing the company’s debt.

    By Nov. 21, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images

    Pfizer, BioNTech start study testing next COVID-19 vaccine

    The new candidate is meant to provide broader immunity over a longer period of time and is part of the companies’ strategy to stay ahead of a shifting coronavirus threat.

    By Nov. 17, 2022
  • A photo of Regeneron's Tarrytown, NY headquarters.
    Image attribution tooltip

    Regeneron teams up with CytomX to develop dual-targeting cancer drugs

    Regeneron will pay CytomX $30 million to try to create bispecific antibody drugs that are safer and have a wider reach than existing treatments.  

    By Nov. 17, 2022
  • Q&A // Emerging biotech

    Eli Lilly’s Julie Gilmore on finding up-and-coming companies and backing small biotechs

    Only a small fraction of the companies Lilly evaluates get into its incubator, according to Gilmore. Here’s how the big pharma selects them.

    By Nov. 15, 2022
  • Beta-Amyloid Plaques and Tau in the Brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.

    Trial failures end latest hope for Roche’s Alzheimer’s drug

    Eight years after gantenerumab failed a Phase 3 study, the drug came up short in late-stage testing again, proving unable to meaningfully slow cognitive decline in two closely watched trials. 

    By , Nov. 14, 2022
  • Two hikers climbing up a snow mountain during sunrise
    Image attribution tooltip
    Buena Vista Images via Getty Images
    Sponsored by Lumanity

    Crossing the new real world data landscape

    Learn about key factors and trends in RWE and why a data luminary is crucial to your success.

    Nov. 14, 2022
  • GlaxoSmithKline CEO Emma Walmsley
    Image attribution tooltip
    Courtesy of GSK Flickr page

    Under FDA pressure, GSK limits use of ovarian cancer drug

    The drugmaker’s decision is the latest fallout from safety concerns that have emerged in testing of so-called PARP inhibitors, resulting in withdrawals by Merck & Co., AstraZeneca and Clovis Oncology. 

    By Nov. 11, 2022
  • Image attribution tooltip
    Carl Court via Getty Images

    EMA backs restrictions on certain immune-regulating drugs

    Once the European Commission signs off, use of several so-called JAK inhibitors sold by Eli Lilly, Pfizer and other drugmakers will be limited among smokers and patients who are at high risk of certain health complications. 

    By Nov. 11, 2022